一分钟看懂
这是一项关于胶质瘤的I 期研究,登记的药物或干预包括Dual-target CAR-NK cells;Cyclophosphamide;Intracranial catheter/reservoir for locoregional delivery;Fludarabine,当前状态为招募中。登记地点显示中国深圳有研究中心记录。是否仍有名额以及是否值得进一步询问,需要向研究中心确认。
药物或干预
Dual-target CAR-NK cells;Cyclophosphamide;Intracranial catheter/reservoir for locoregional delivery;Fludarabine · I 期
登记条件中文摘要
年龄范围:18岁至75岁
登记的基本范围为不限性别,年龄18岁至75岁;以下仅摘录8项专业入选条件,需结合英文原文并由研究团队确认。
登记记录列出8项主要排除条件,具体医学含义需结合英文原文并由研究团队确认。
中国哪些地方有记录
以下地点来自登记信息,不代表此刻仍有名额;请向研究中心确认最新情况。
- Peking University Shenzhen Hospital · 深圳
入选条件原文摘录
以下为摘录,请打开原始登记查看完整入排标准。
- * Age 18 to 75 years at the time of consent.
- * Histologically confirmed glioblastoma (WHO grade 4) or diffuse high-grade glioma (WHO grade 3 or 4) that is recurrent or progressive after standard therapy.
- * Planned clinically indicated tumor resection or stereotactic biopsy (or availability of adequate archived tumor tissue) to support antigen testing and locoregional catheter placement.
- * Tumor demonstrates expression of at least two of the following antigens above protocol-defined thresholds: IL13Rα2, EGFR (wild-type) and/or EGFRvIII, B7-H3 (CD276).
- * Karnofsky Performance Status (KPS) ≥ 60.
- * Adequate organ function (hematologic, renal, hepatic) as defined by protocol laboratory criteria.
- * Ability to undergo brain MRI with contrast (unless contraindicated and alternative imaging is permitted).
- * Negative pregnancy test for women of childbearing potential; agreement to use effective contraception during study participation and for a protocol-defined period after infusion.
联系前需要确认
请继续确认中心是否启动、疾病分型、既往治疗、检查费用和知情同意安排。
查看登记信息
登记号:NCT07551336;登记信息更新于 2026-11-12;本站同步于 2026-11-21。